Skip to content
  • Facebook
  • Twitter
This translation is automatically provided by Google; please refer to the original English version for appropriate wording.
Take on Typhoid

Take on Typhoid

  • Home
  • Why Typhoid?
    • Typhoid & Related Salmonelloses
    • Global Research
    • Links & Resources
  • The Issues
    • Vaccines
    • WASH
    • Drug-Resistant Typhoid
    • Treatment
    • Diagnostics
    • Typhoid intestinal perforation
    • Related Issues
  • Resources & Tools
    • Talk About Typhoid
    • Global Policy
    • Country Tools
    • Infographics
    • Fact Sheets
    • TCV Cost-effectiveness
    • Share on Social
  • Blog & News
    • Blog
    • News
    • Publications
    • Newsletter
  • International Conference
    • Past Conferences
    • Conference Travel
  • About Us
    • About the Coalition against Typhoid
    • About the Typhoid Vaccine Acceleration Consortium

Superbugs: New strain of ‘highly’ drug resistant typhoid detected

Posted on November 20, 2018 by admin
  • Highly drug resistant strains of typhoid fever have been discovered in Bangladesh, raising concerns that antibiotics could be rendered an ineffective treatment for the disease within just a few years.

Post navigation

Typhoid Fever Cases Increasing Among U.S. Kids, but Risk Still Low
Global Typhoid Vaccine Market 2018: Merck, GlaxoSmithKline, PaxVax, Actiza Pharmaceutical

Newsletter Signup

Recent Posts

  • TCV: An early defense against typhoid in extreme weather conditions

  • Can better diagnostics improve typhoid prevention and treatment?

  • Réponse immunitaire robuste à la dose de rappel du vaccin antityphoïdique chez les enfants âgés de cinq ans au Malawi

  • Robust immune response to typhoid booster vaccination at five years in Malawi

  • The journey of a vaccine: from production to protection

cat
685 West Baltimore Street, Room 480
Baltimore, MD 21201-1509
Coalition against Typhoid
2175 K Street, NW, Suite 400
Washington, DC 20037
© 2018. Coalition Against Typhoid. All Rights Reserved.
  • Contact Us
  • Privacy Policy
  • Facebook
  • Twitter
Top